Zenas BioPharma, Inc. (ZBIO)

It follows an earlier April inducement ... and earnings updates. Investors may track how recurring equity-based compensation, the active $200,000,000 ATM capacity, and future trial milestones interact with ZBIO’s position below its $24.45 200-day moving average. restricted stock units, nasdaq ...

See the latest BridgeBio Pharma Inc stock price (BBIO:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

The company has a debt-to-equity ratio of 1.04, a current ratio of 11.94 and a quick ratio of 11.94. The stock has a market cap of $1.09 billion, a P/E ratio of -2.04 and a beta of -0.61. Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) last announced its quarterly earnings data on Wednesday, ...

Adding a powerful vote of confidence, CEO Leon O. Moulder Jr. purchased 60,000 shares of the company’s common stock on May 18, 2026, in transactions totaling approximately $1.01 million, with shares acquired at prices ranging from $16.59 to $16.97 per share. Insiders have traded ZBIO stock on ...

Zimmer Biomet reported fresh quarterly results and reaffirmed its outlook, while also increasing its fiscal 2026 share repurchase expectations to as much as $1 billion.